EDITORIALHospital,SchoolofMedicine,T(NSCLC),particularlyintheareasofimmunotherapyandtar-SocietyofClinicalOncologyGuidelinesforNSCLC(CSCONSCLC),akeyreferenceforclinicaldationsforapplicabilityinreal-worldscenariosinChina.ThisEGFR,ALK,RET,andMETmutations,toprovidepractical,tions.ForpatientswithNSCLCwithoutoncogenicdriverORCIDID:/0000?2025TheAuthors.CreativeCommonsAttribAdvancedNSCLCwithdrivergenemutationsCommondrivergenemutationsinNSCLCinChina,haveemergedinrecentyears.Third-OnthebasisoftheresultsfromtheIBtinib,befotertinib(NMPA)approvedbefotertinibforbotsolidifyingtheroleofthird-generationEGFRinhibitorsinthetreatmentofadvancedNSCLC.treatments.InthephaseIIIFLAURA2trial,osimertinibcom-3anewfirst-linetreatmentforEGFRNSCLC;t2.每日分享：6+份行研精選、3個(gè)行業(yè)主題3.報(bào)告查找：群里直接咨詢，免費(fèi)協(xié)助查找4.嚴(yán)禁廣告：僅限行業(yè)報(bào)告交流，禁止一切無(wú)關(guān)信息78Administration(FDA).Additionally,intheMARIPOSAstudyacombinationoflazertinibandamivantamab(EGFR-METinChina,thiscombinationisincludedonlsectionoftheupdatedguidelines.IntheMARIPOSA-2trial,higherORR(64%and63getingtyrosinekinaseinhibitor(TKI),initiallydemonstratedmoderateefficacyinthephaseIIEXCLAIMtrial.However,aphaseIIItrial,theFDAwithdond-linetreatmentintheWONKONG-6study6.SunvozertinibthePAPILLONstudy,amivantprolongedPFSinpatientswithadvancedNSCLCwithEGFRadvancementsinALKinhibitors,advancedNSCLCwithALKachievesignificantlylongerPFSthancrizotiaftertheINSPIREstudy,theNMPAapprovediruplinalkibasafirst-linetreatmentforALK-fusionadvancedNSCLCcrizotinib(HR=0.34,P<0.0001)7.Furthermore,iruplinalkibORRof69.9%intheINTELLECTstudy,thusfurtherconfirm-c-Met/ALK/ROS1isenvonalkib.Comparedwithcrizotinib,ALK-fusionNSCLC,including6internationaldrugsand2RaredrivergenemutatiROS1fusionoccursprimarilyinlungadenocarcinomawith-outsmoking.ThecurrentCSfor2TKIstargetingROS1:repotrectinibandbilityinpatientswithROS1-fusionNSCLC,asshownintheTRIDENT-1study,withanORRof79%andmedianPFSoffftherapydesignationbythsecond-linetreatmentofROS1-fusionNSCLC.Additionally,NSCLCwithBRAFV600mutationhashistoricallyderivedftionofencorafenib(BRAFinhibitor)andbinimetinib(MEKinhibitor)asafirst-linetreatmentforBRAFV600NSCLCtreatmentofBRAFV600advancedNSCLC.Therefore,the2024CSCOguidelinesincludafirst-linetreatmentforBRAFV600advancedNSCgradeIIIrecommendation.enableprecisionmediNSCLC,andtraditionalplintroductionofthenewRETinhibitorsprNSCLC.IntheLIBRETTO-001study,selpercatinibachievedond-linetreatment17.TheLIBRETTO-431study,presentedARROWstudyinChinesepatientswithRETfusion-positiveNSCLCindicatedanORRof83%andamedianPFSof12.7NMPAforfirst-linetreatmentofRETfusionNSCLC,anditsInadvancedNSCLCwithKRASG12Cmutations,multiplegroup.InpostlinetreatmentofadvancedNSCLCwithKRASTROP2-targetingADCshaveallshownpromisingresults.fpatientswithNSCLCinChina,andthesemutationsorampli-ancetoEGFR-TKIsinNSCLC.TheDESTINY-Lung02studycan(T-DXd)inpreviouslytreatedpatieNSCLC,achievingORRsof50.8%and73.3%atdosesofforHER2NSCLCandwasdesignateda“NMPAforsecond-linetreatmentofHER2NSCLC.ThephaseIIIPAPILLONstudyhasshownthatamivantamabcombined(73%vs.47%)inpatientswithofthecurrentunavailabilityandlackofapprovalofthisADCAdvancedNSCLCwithoutdriverImmunotherapywithdrivergene-negat8080INSPIREALK9withdrivergene-negativeadvancedNSCLCwithPS=2.widepatientpopulation,tandpharmacoeconomicconsiderations.Thiscomprehen-NSCLC.Theefficacyandaccessibilityofthedrugsassociatedtheintegrationofemergingmodalities,suchasADCsandlandscapeforadvancedNSCLCintheyearstocome.FuturedirectionsemphasizetheimportanceAuthorcontributionsADCsmentforpatientswithadvancedNSCLCwithwildtypedrivergenes.Dato-DXd,aTROP2-targetingADC,hasshownposi-post-treatmentDato-DXdadministration.Dato-DXdeffec-apy.Innon-squamousNSCLC,theDato-DXdtreatmentpatients.The2024editionoftheCSCONSCLCguidelinesGrantsupportLeader(GrantNo.21XD1423200).ConflictofintereststatementAcknowledgmentsWethankallmembersoftheCSCONSCLCGuidelinesWorkingGroup.1.LuS,ZhouJ,JianH,WuL,ChengY,EGFR-mutatedlocallyadvancedormeta822.LuS,ZhangY,ZhangG,ZhouJ,CangS,ChengY,etal.Efficacyandsafetyofbefotertinib(D-0316)inpatientswithEGFRT790M-mutatedNSCLCthathadprogressedafterpriorEGFRtyrosine3.PlanchardD,J?nnePA,ChengY,YangJC,YanagitaniN,KimSW,etal.OsimertinibwithadvancedNSCLC.NEnglJMed.24.LuS,ChoBC,LeeJS,LeeSH,DanchaivijitrP,LiuB,etal.LBA10AmivantamabpluslazertiamongAsianpatientswithEGFR-mutatecelllungcancer(NSCLC):MARIPOSAsubgroupanalysis.Ann5.J?nnePA,WangBC,ChoBC,ZhaoJ,LiJ,HochmairMJ,etEXCLAIM-2:phaseIIItrialoffirst-line(1L)mobocertinibversusmetastaticnon-small-celllungcancerandEGFRemutation(WU-KONG6):single-arm,open-label,multicentre,7.ShiY,ChenJ,YangR,WuH,WangZ,YangW,etal.Iruplinalkib(WX-0593)versuscrizotinibinALKTKI-naivelocallyadvancedormetastaticALK-positiveNSCLC:interimanalysisofarandomized,open-label,phase3study(INSPIRE).JThorac8.ShiY,ChenJ,ZhangH,ZhangZ,ZhangY,WangZ,etal.Efficacyandsafetyofiruplinalkib(WX-0593)inALK-positivecrizotinib-arm,multicenterphaseIIstudy(INTELLECT).BMCMed.2023;9.YangY,MinJ,YangN,YuQ,ChengY,ZhaoY,etal.Envonalkibversuscrizotinibfortreatment-naiveALK-positivenon-smallcell10.DrilonA,CamidgeDR,LinJJ,KimSW,SolomonBJ,DziadziuszkoR,etal.RepotrectinibinROS1fusion-positivenon-small-celllungpharmacokineticsofunecritinib(TQ-B3101)forpatientswithROS1positiveadvancednon-smallcelll12.RielyGJ,SmitEF,AhnMJ,FelipE,RamalingamSS,TsaoA,etPhaseII,open-labelstudpatientswithBRAFV600-mutantmetastaticnon-small-cell13.MazieresJ,PaikPK,GarassinoMC,LeX,SakaiH,VeillonR,etal.Tepotinibtreatmentinpatiesmallcelllungcancer:long-termfollow-upoftheVISIONphase2nonrandomizedclinicaltrial.JAMAOncol.20214.YangJJ,ZhangY,WuL,HuJ,WangZH,ChenJH,etal.Vebreltinibskippingmutation:amulticenter,single-arm,phaseIIKUNPENG15.YuY,ZhouJ,LiX,GotoK,MinX,NishinoK,etal.Gumarontinibinpatientswithnon